TG Therapeutics Launched FDA Approved Product  BRIUMVI™ for Patients with Relapsing Forms of MS

TG Therapeutics 
TG Therapeutics (TGTX) is a commercial stage, biopharmaceutical company developing and commercializing novel treatments for B-cell diseases. The firm’s research pipeline has several investigational medicines. TG Therapeutics has been granted U.S. FDA approval of its product BRIUMVI™ (ublituximab-xiiy), for adult patients with relapsing forms of multiple sclerosis, to include clinically isolated syndrome . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.